NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
The experimental mRNA shot, tested in macaques, generated a stronger immune response and dramatically reduced the number of ...
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians ...
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...
While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...
Health Canada authorized Moderna's updated COVID-19 vaccine on Tuesday to roll out in fall and winter immunization campaigns.
The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...